1990
Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine.
Shapiro E, Berg A. Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine. Pediatrics 1990, 85: 643-7. PMID: 2179854, DOI: 10.1542/peds.85.4.643.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType b polysaccharide vaccineH influenzae type b polysaccharide vaccineHaemophilus influenzae type b polysaccharide vaccinePolysaccharide vaccineProtective efficacyMonths of ageVaccine failureInvasive diseaseH influenzae type b.Immunization Practices Advisory CommitteeH influenzae type bVaccine protective efficacyRandomized clinical trialsInfluenzae type bAvailable epidemiologic dataNormal serum concentrationsYears of ageTotal immunoglobulinSerum concentrationsImmune deficiencyClinical trialsEpidemiologic dataHemolytic complementVaccineChildren 18
1987
USE OF HAEMOPHILUS VACCINE IN CONNECTICUT
Shapiro E, Lichtman J, Petersen L, Hadler J, Leventhal J. USE OF HAEMOPHILUS VACCINE IN CONNECTICUT. Pediatric Research 1987, 21: 287-287. DOI: 10.1203/00006450-198704010-00719.Peer-Reviewed Original ResearchMonths of ageGroup day carePrepaid health maintenance organizationHaemophilus influenzae type bYale-New Haven HospitalDay careRates of immunizationInfluenzae type bHealth maintenance organizationRisk of diseaseHaemophilus vaccineHib diseaseHib vaccineChildren 24Universal immunizationPublic clinicsIndigent patientsCare statusPrivate physiciansVaccineChildren 18Maintenance organizationMonthsPhysiciansType B